Baseline clinical features, medication details and radiological findings of the 66 patients enrolled
| Characteristics | No (%) | Median | 1st; 3rd Quartile |
|---|---|---|---|
| Age at study visit (years) | 10.7 | 8.5; 14 | |
| Disease duration (years) | 4.2 | 2; 6.5 | |
| Number active joints | 8.5 | 4; 24 | |
| No of joints with LOM | 7.0 | 3; 22 | |
| VAS physician (0=no activity, 10 cm=maximum activity) | 7.5 | 4.8; 9 | |
| CHAQ score (0=best, 3=worst) | 0.75 | 0.125; 1.25 | |
| VAS pain (0=no pain; 10 cm=maximum pain) | 3.7 | 1; 5.2 | |
| Global VAS patient (0=very good; 10 cm=very poor) | 3.3 | 0.9; 5.3 | |
| JADI-A (range 0–72) | 0.0 | 0; 2 | |
| JADAS-71 range (0–101) | 22.4 | 12.5; 41 | |
| CRP (mg/dl) | 2.4 | 0.5; 7.8 | |
| ESR (mm/1st h) | 38 | 18; 63 | |
| MRI bone erosion score (range 0–4) | 3 | 1; 6 | |
| MRI bone erosion score reduced version (range 0–4) | 3 | 1; 5 | |
| RAMRIS bone erosion score (range 0–10) | 3.8 | 2; 9 | |
| MRI bone marrow oedema score (range 0–2) | 3 | 1; 8 | |
| RAMRIS bone marrow oedema score (range 0–3) | 3.5 | 1; 9 | |
| RAMRIS synovitis score | 3 | 2.7; 5 | |
| Adapted version Sharp/van der Heijde score | 13.5 | 2; 25.3 | |
| Poznanski score | −1.4 | −2.6; −0.4 | |
| Second-line drug treatment, n (%) | |||
| Methotrexate | 26 (39.4) | ||
| Ciclosporin | 4 (6.1) | ||
| Biological treatment, n (%) | |||
| Etanercept | 8 (12.1) | ||
| Anakinra | 2 (3.0) | ||
| Systemic corticosteroid treatment, n (%) | 17 (25.8) | ||
CHAQ, Childhood Health Assessment Questionnaire; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; JADAS-71, Juvenile Arthritis Disease Activity Score for 71 joints; JADI-A, Juvenile Arthritis Damage Index Articular score; LOM, limited range of motion; RAMRIS, Rheumatoid Arthritis MRI Score; VAS, visual analogue scale.